Cardiorenal protection: a risk-based approach to managing type 2 diabetes in addition to glycaemic control
Literature
•
AstraZeneca
About the CPD course
An interactive and engaging presentation developed for UK based GPs; practice based and primary care network pharmacists and nurses; sharing the recent NICE updates to the NG28 guidelines for Type 2 diabetes management; This presentation provides a comprehensive background to the value of a risk-based approach both clinically and for patient-outcomes; and includes meta-data analysis results; As well as outlining the data supporting the revised approach; it details guidance on how to implement the new treatment strategy in daily practice to improve patient outcomes;
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines.
Our Purpose is to push the boundaries of science to deliver life-changing medicines. We believe the best way we can achieve our Purpose is to put science at the centre of everything we do. Science defines who we are. It is why we come to work every day and is part of our DNA. But this is only half of the story. We know that we do not have all the answers. We want to share ideas because we believe it results in better medicines. We want the way we work to be inclusive, open and collaborative. This approach runs through all that we do.
